GI Oncology Highlights from ASCO
Comments have been provided by Associate Professor Mustafa Khasraw. POLO This was a phase III trial which found that... Read More
Recruitment strategy revised for NABNEC
Trial update: NABNEC The NABNEC trial is almost halfway to its accrual target, with 31 participants at the end... Read More
June 2019: An update from CEO Russell Conley
Dear Members, At the beginning of this month I attended the ASCO Annual Meeting in Chicago. At the meeting... Read More
Preliminary results for ALT-GIST released
The preliminary results of the ALT-GIST clinical trial were released at the ASCO Annual Meeting. ALT-GIST was a phase... Read More
May 2019: An update from the CEO
Dear Members, Monday 20 May was International Clinical Trials Day. This was an opportunity to reflect on the dedication... Read More
May 2019: AGITG Trial Updates
ALT-GIST results to be presented at ASCO The preliminary results of the phase II ALT-GIST study will be presented... Read More
Report from the COSA Cancer Survivorship Conference: Jan Mumford & Robin Mitchell
The Clinical Oncology Society of Australia (COSA) Cancer Survivorship Conference was held from 28-29 March. The event hosted... Read More
AGITG Joint Working Party Meeting 10 May 2019
AGITG Joint Working Party Meeting 10 May 2019 May 22, 2019 Lower GI Working Party Trial Updates SPAR recruitment is underway... Read More
AGITG Outstanding Site Award
Clinical trial sites actively involved in AGITG Studies are invited to submit a brief application of 500 words... Read More
AGITG Lower GI Working Party: 13 March 2019
APOLLO1: Australian Peritoneal Organoid guided therapy to Lengthen Life in patients without Opportunity for Cure: a pilot trial. This... Read More
April 2019: Trial news
The DYNAMIC Studies AGITG currently has three studies investigating ctDNA in gastro-intestinal cancers. The three trials will help determine... Read More
The first Japanese site in an AGITG trial opens for INTEGRATE II
The first AGITG trial site in Japan has opened for the INTEGRATE II study in gastro-oesophageal cancer. National Cancer... Read More
John Zalcberg OAM Award Open for Applications
The John Zalcberg OAM Award for Excellence in AGITG Research Pictured – L to R: Professor Tim Price AGITG... Read More
Upper GI Working Party Meeting: 13 February 2019
Concept Updates from previous meetings: NAP CAPABIL: Single arm phase II trial of NAB-paclitaxel in combination with capecitabine as second-line... Read More
How the GI Cancer Institute’s research is developed
The GI Cancer Institute’s research and clinical trials are developed through a robust, scientific process. The studies we... Read More
Professor Tim Price to lead the 2019 Gutsy Southern Alps Challenge in New Zealand
Professor Tim Price, Chair of the GI Cancer Institute, will lead the Gutsy Southern Alps Challenge in New... Read More
Our Research Priorities: What is key to the future of research?
During 2017 our Board of Directors and management created a revised Strategic Plan for the organisation and its... Read More
Gastro-intestinal surgeons receive Australia Day honours
Excellence in gastro-intestinal (GI) cancer research and treatment has been recognised on the Australia Day 2019 Honours List,... Read More
Cancer drugs made available on PBS for gastro-intestinal cancer patients
The Department of Health has announced on Saturday 1 December that five new cancer listings have been made... Read More
Interview: Clinical Research Fellow Dr David Lau
Dr David Lau is three months into his fellowship at Royal Marsden Hospital, London. “It has been incredible,” he... Read More